# Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

> **NCT04948008** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Shenzhen People's Hospital** · enrollment: 8 (estimated)

## Conditions studied

- Familial Hypercholesterolemia - Homozygous
- Lipid Metabolism Disorders
- Proprotein Convertase Subtilisin/Kexin 9

## Interventions

- **BIOLOGICAL:** IBI306

## Key facts

- **NCT ID:** NCT04948008
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-05
- **Primary completion:** 2020-07-15
- **Final completion:** 2022-12-31
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948008, "Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04948008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*